Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/10405
|
| Title: | Sequential use of everolimus and sunitinib in treating WHO grade 1 and 2 pancreatic neuroendocrine tumors-retrospective multi-center study in Taiwan |
| Authors: | Liu, CT;Chen, LT;Chen, YY;Chen, JS;Su, YL;Chou, WC;Lu, CH;Ku, FC;Chen, MH;Shan, YS |
| Contributors: | National Institute of Cancer Research |
| Abstract: | Background: There are at least four different systemic treatments for grade 1 and 2 advanced pancreatic neuroendocrine tumors (pNETS), including chemotherapy, somatostatin analogues, sunitinib and everolimus. Sequential sunitinib and everolimus in renal cell carcinoma have led to an improvement in overall survival. Theoretically, this is believed to occur in pNETS but not been proved, yet. The purpose of this retrospective study was to compare outcomes for patients with pNETS receiving two targeted therapies, everolimus and sunitinib, sequentially. Methods: This is a retrospective multi-center registration study. The primary objective was to assess progression-free survival (PFS) of front-line everolimus compared with front-line sunitinib. Secondary objectives was safety profile of both agents. Results: From Feb. 1st. 2008 to Oct. 31th. 2014, twenty-four patients were included in seven medical centers in Taiwan. Overall median age was 52.6 years, and most patients were women (58.3%). Median PFS was 14.2 months with front line everolimus, 4.9 months with front line sunitinib (hazard ratio [HR], 0.34; 95% confidence interval (CI), 0.13 to 0.90, p = 0.08). After discontinuing from front line targeted therapy, median PFS was 13.0 months with everolimus in later line, 7.2 months with sunitinib in later line (HR, 1.79; 95% CI, 0.65 to 4.94, p = 0.64). There is 36.5% of patients discontinued sunitinib due to adverse events, no matter front or later line, compared to 6.7% patients while receiving everolimus. Conclusions: Sequential use of everolimus and sunitinib in treating patient with advanced pNETS may be an option, but prospective and randomized trials that seek for the sequence of targeted therapies are highly needed. |
| Date: | 2016-12 |
| Relation: | Annals of Oncology. 2016 Dec;27(Suppl. 9):Meeting Abstract 420P. |
| Link to: | http://dx.doi.org/10.1093/annonc/mdw590.006 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000393980600419 |
| Appears in Collections: | [陳立宗] 會議論文/會議摘要
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI000393980600419.pdf | | 72Kb | Adobe PDF | 217 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
